Kirkland Represents SciClone Pharmaceuticals on Voluntary Share Buy-Back Offer

Kirkland & Ellis advised SciClone Pharmaceuticals (Holdings) Limited (HKSE: 6600), a biopharmaceutical company with an integrated platform for product development and commercialization, on its HK$780 million voluntary conditional cash offer to buy-back up to 77,534,791 shares at HK$10.06 per share, representing approximately 11.16% of SciClone Pharmaceuticals’ total issued share capital. The offer is subject to, among other things, approvals by the independent shareholders of SciClone Pharmaceuticals. 

Read SciClone Pharmaceuticals’ announcement